A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Clinical trial NCT04510285 · TERMINATED
Trial details
- NCT number
- NCT04510285
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-10
- Primary completion
- 2022-12-30
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.